Arvinas Inc. (ARVN)
ARVN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1655759/000162828026011226/0001628280-26-011226-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ARVN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2018 |
| SEC CIK | 0001655759 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $262.6M |
| Net income | -$80.8M |
| Operating income | -$118.5M |
| Net margin | -30.8% |
| Operating margin | -45.1% |
| Revenue growth | -0.3% |
| Cash | $142.9M |
| Total assets | $717.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.7× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $88.0M cash; operating cash flow -$39.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 65,485,006 (2026-10-30); 64,224,294 a year earlier; 55,025,504 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-11-03 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $268K, sold $1.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $500K | -$53.9M | -$10.4M | $88.0M | $400K | $275.3M | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $249.7M | $169.4M | -$48.3M | $94.3M | $500K | $316.7M | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | $15.6M | -$57.6M | -$69.2M | $87.3M | $500K | $89.4M | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | $9.5M | -$67.4M | -$30.4M | $142.9M | $600K | $262.6M | 10-K 2026-02-24 |
| Q3 2025 2025-09-30 | $41.9M | -$35.1M | -$59.1M | $101.5M | $600K | $312.3M | 10-Q 2025-11-05 |
| Q2 2025 2025-06-30 | $22.4M | -$61.2M | -$95.4M | $114.9M | $700K | $372.8M | 10-Q 2025-08-06 |
| Q1 2025 2025-03-31 | $188.8M | $82.9M | -$88.9M | $81.0M | $700K | $426.9M | 10-Q 2025-05-01 |
| Q4 2024 2024-12-31 | $59.2M | -$45.1M | -$84.1M | $100.5M | $800K | $263.4M | 10-K 2026-02-24 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-11-03 |
| Latest annual report | 10-K | 2026-02-24 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 605 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +6.4% |
| 1 month | -0.3% |
| 3 months | -24.3% |
| Year to date | -42.5% |
| 1 year | -32.6% |
| From 52-week high | -50.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| MPLT | MapLight Therapeutics Inc. | $6.90 | -4.83% | $446.9M |
| EOLS | Evolus Inc. | $6.63 | -4.74% | $438.8M |
| DMAC | DiaMedica Therapeutics Inc. | $8.33 | -5.23% | $449.5M |
| ASMB | Assembly Biosciences Inc. | $21.29 | +0.80% | $436.0M |
| OVID | Ovid Therapeutics Inc. | $2.40 | -5.51% | $453.0M |
| BLSM | BlossomHill Therapeutics Inc. | $13.65 | -2.64% | $433.9M |
| CTMX | CytomX Therapeutics Inc. | $1.99 | -2.70% | $432.7M |
| AVTX | Avalo Therapeutics Inc. | $7.37 | -5.03% | $426.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier